Matthew McIntosh

TL;DR: There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.

TL;DR: It is concluded that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD awaiting kidney transplants.

TL;DR: For recipients on cyclosporine/mycophenolate mofetil/P with no AR at 90 days, the chance of developing subsequent AR is small; if P is tapered and withdrawn, the risk increases, but the majority remain free of acute and chronic rejection.

TL;DR: It is concluded that calcineurin inhibitor-free immunosuppression can be safe and effective in pediatric living-donor renal transplantation, however, further modifications that are designed to lessen early rejection rates and decrease complications should be tested before this approach is used routinely.

TL;DR: It is demonstrated that the incidence of acute rejection or graft failure in pediatric patients is not improved by OKT3 induction therapy relative to cyclosporine induction, and graft survival was inferior for children aged 6’yr or younger.